PharmaCyte Biotech Inc
PMCB.OQ- Latest Trade
- trading higher2.09USD
- Change
- 0
- % Change
0.00%
- Day Range
- 2.06 - 2.17
- 52-Week Range
- 1.80 - 9.98
As of Jun 24 2022. Values delayed up to 15 minutes
- Previous Close
- 2.09
- Open
- 2.11
- Volume
- 51,469.00
- 3 Month Average Trading Volume
- 9.52
- Shares Out (Mil)
- 20.72
- Market Cap
- 43.93
- Forward P/E
- -8.83
- Dividend Yield
- -99,999.99
Key Statistics
3 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 0.48
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -7.63
- Return On Equity (TTM)
- -7.54
2021 (millions USD)
About PharmaCyte Biotech Inc
Company Information
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
Address
12510 PROSPERITY DRIVE, SUITE 310SILVER SPRING, MD
20904-1643
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Kenneth L. Waggoner
- Chairman of the Board, President, Chief Executive Officer, General Counsel
- Carlos A. Trujillo
- Chief Financial Officer, Director
- Gerald W. Crabtree
- Chief Scientific Officer, Director
- Walter H. Gunzburg
- Chief Scientific Officer
- Michael M. Abecassis
- Independent Director
- Thomas Liquard
- Independent Director
- Matthias Lohr
- Independent Director
- Raymond C.F. Tong
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes